JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jazz Pharmaceuticals (JAZZ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential, robust analyst support, and positive developments in its pipeline, making it a compelling investment opportunity.
The MACD is negative and expanding (-2.146), indicating bearish momentum. RSI at 32.222 is near oversold territory, suggesting potential for a rebound. The stock is trading near its support level (S1: 222.966), which could serve as a solid entry point for long-term investors.
Collaboration with AbCellera to develop multispecific antibodies for gastrointestinal cancers, with a potential value of up to $848 million.
Strong Phase 3 HERIZON data supporting Ziihera's commercial potential.
Positive analyst sentiment with multiple price target upgrades and a consensus on robust growth prospects.
Current bearish technical indicators, including negative MACD and price trading below pivot levels.
Lack of significant hedge fund or insider trading activity, indicating neutral sentiment from major stakeholders.
No financial data provided for analysis. However, Q1 results were strong, with revenue of $1.069B beating consensus estimates, driven by Xywav and Zepzelca performance.
Analysts are overwhelmingly positive on JAZZ, with multiple upgrades and price target increases. UBS upgraded the stock to 'Buy' with a $307 price target, citing strong execution and growth potential. Barclays and TD Cowen also raised their price targets, reflecting confidence in the company's long-term growth trajectory.
